Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 3/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2731065 | 0.89 | BRD4 (0.41) | BRD4CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL737361 | 0.82 | MAPK1 (0.37) | KMT2AKDM4E | |
| SCHEMBL1026647 | 0.81 | BRD4 (0.46) | BRD4CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL22279768 | 0.81 | BRD4 (0.46) | BRD4CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL28009406 | 0.81 | BRD4 (0.46) | BRD4CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL1467839 | 0.81 | ALDH1A1 (0.43) | KMT2AKDM4EALDH1A1 | |
| SCHEMBL2153225 | 0.80 | CHRNB2 (0.41) | BRD4CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL2772847 | 0.80 | BRD4 (0.39) | BRD4CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL20300486 | 0.80 | KMT2A (0.30) | KMT2AALDH1A1 | |
| SCHEMBL21987729 | 0.80 | BRD4 (0.36) | BRD4KMT2ATP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4159727-B1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC INC (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12559506-B2 | Indazole based compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| EP-4695242-A1 | NOVEL SUBSTITUTED PYRROLE COMPOUNDS, COMPOSITIONS COMPRISING THE SUBSTITUTED PYRROLE COMPOUND, AND METHODS OF USE THEREOF | Meta Pharmaceuticals (HK) Limited (HK) | 2026-02-18 | — | — | EP | disclosed |
| US-20250388593-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2025-12-25 | — | — | US | disclosed |
| EP-4650348-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | Mitsubishi Tanabe Pharma Corporation (JP) | 2025-11-19 | — | — | EP | disclosed |
| US-12415796-B2 | Inhibitors of (αv)(β6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2025-09-16 | — | — | US | disclosed |
| EP-4610260-A1 | ARYL HETEROCYCLIC KV1.3 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | Shanghai Shenshi Wise Technology Co., Ltd. (CN) | 2025-09-03 | — | — | EP | disclosed |
| US-20250163061-A1 | INHIBITORS OF MENIN-MLL INTERACTION | BALA THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| CN-119698412-A | 5-HT2A receptor agonist, and preparation method and application thereof | 上海翊石医药科技有限公司 | 2025-03-25 | — | — | CN | disclosed |
| WO-2025021120-A1 | 5-HT2A RECEPTOR AGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翊石医药科技有限公司 | 2025-01-30 | — | — | WO | disclosed |
| EP-2734529-A1 | BTK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2014-05-28 | — | — | EP | disclosed |
| US-8592590-B2 | Tetrahydrotriazolopyridine compounds as selective MGLU5 receptor potentiators useful for the treatment of schizophrenia | ELI LILLY AND COMPANY (US) | 2013-11-26 | — | — | US | disclosed |
| EP-2519521-B1 | TETRAHYDROTRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE MGLU5 RECEPTOR POTENTIATORS USEFUL FOR THE TREATMENT OF SCHIZOPHRENIA | LILLY CO ELI (US) | 2013-11-20 | — | — | EP | disclosed |
| WO-2013010380-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-01-24 | — | — | WO | disclosed |
| EP-2519521-A1 | TETRAHYDROTRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE MGLU5 RECEPTOR POTENTIATORS USEFUL FOR THE TREATMENT OF SCHIZOPHRENIA | Eli Lilly and Company (US) | 2012-11-07 | — | — | EP | disclosed |
| US-20120252838-A1 | TETRAHYDROTRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE MGLU5 RECEPTOR POTENTIATORS USEFUL FOR THE TREATMENT OF SCHIZOPHRENIA | ELI LILLY AND COMPANY (US) | 2012-10-04 | — | — | US | disclosed |
| US-8044206-B2 | Nitrogen—containing heterocyclic derivatives having 2,6-disubstituted styryl | ASTELLAS PHARMA INC. (JP) | 2011-10-25 | — | — | US | disclosed |
| WO-2011082010-A1 | TETRAHYDROTRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE MGLU5 RECEPTOR POTENTIATORS USEFUL FOR THE TREATMENT OF SCHIZOPHRENIA | ELI LILLY AND COMPANY (US) | 2011-07-07 | — | — | WO | disclosed |
| US-20070099956-A1 | Nitrogen-containing heterocyclic derivatives having 2, 6-disubstituted styryl | ASTELLAS PHARMA INC. AND KOTOBUKI PHARMACEUTICAL CO., LTD. | 2007-05-03 | — | — | US | disclosed |
| EP-1602645-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVE HAVING 2,6-DISUBSTITUTED STYRYL | Astellas Pharma Inc. (JP) | 2005-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163061-A1 | INHIBITORS OF MENIN-MLL INTERACTION | MLLT1, MEN1, BMI1 | BRD4 81/4885CHRNB2 3827/4885CHRNA4 4222/4885 |
| US-12559506-B2 | Indazole based compounds and associated methods of use | LRRK2, CRBN, CLK2 | BRD4 242/4885CHRNB2 915/4885CHRNA4 1833/4885 |
| US-12415796-B2 | Inhibitors of (αv)(β6) integrin | ITGB6, ITGA6, ITGAV | BRD4 879/4885CHRNB2 928/4885CHRNA4 972/4885 |
| US-20070099956-A1 | Nitrogen-containing heterocyclic derivatives having 2, 6-disubstituted styryl | SCN1B, CACNA1B, SCN2A | BRD4 384/4885CHRNB2 650/4885CHRNA4 605/4885 |
| US-20250388593-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | CRBN, CUL1, CBL | BRD4 1339/4885CHRNB2 109/4885CHRNA4 204/4885 |
| US-20120252838-A1 | TETRAHYDROTRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE MGLU5 RECEPTOR POTENTIATORS USEFUL FOR THE TREATMENT OF SCHIZOPHRENIA | GRM5, GRM1, GRIK5 | BRD4 181/4885CHRNB2 290/4885CHRNA4 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.